SB478
Senate · 2026 sessionRepublicanInterim studyPrescription drug affordability reforms
AI-generatedRegulates prescription drug costs by banning spread pricing, requiring pass-through pricing, directing manufacturer rebates toward lowering premiums or point-of-sale costs, banning retroactive fees on clean claims, requiring timely access to pricing lists, and permitting audits.
relative to strengthening prescription drug affordability and pharmacy benefits manager accountability.Official record
Public and Mental HealthInsuranceBusiness and IndustryAI-generated
Division of testimonyComputed by this site
0 submissionsSupport 0Oppose 0Neutral 0
Status
Referred to interim study (Senate) · March 12, 2026- ✓Introduced
- Senate
- House
- Governor
- Law
The record · every submission as filed
0 submissionsNo testimony matches these filters. Clear the search or set position to All.